Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.globenewswire.com/news-release/2024/05/21/2886024/0/en/Erasca-Announces-Closing-of-Underwritten-Offering-of-Common-Stock-and-Full-Exercise-of-the-Underwriters-Option-to-Purchase-Additional-Shares.html
https://www.biopharmadive.com/news/erasca-layoffs-breyanzi-approval-morphosys-novartis/716290/
https://www.globenewswire.com/news-release/2024/05/17/2883986/0/en/Erasca-Announces-Strategic-In-Licensing-of-RAS-Targeting-Franchise.html
https://www.globenewswire.com/news-release/2024/05/17/2883982/0/en/Erasca-Announces-Pricing-of-Underwritten-Offering-of-Common-Stock.html
https://www.globenewswire.com/news-release/2024/05/08/2878154/0/en/Erasca-Reports-First-Quarter-2024-Business-Updates-and-Financial-Results.html
https://www.globenewswire.com/news-release/2024/05/07/2876689/0/en/Erasca-to-Present-at-the-Bank-of-America-Health-Care-Conference.html
https://www.globenewswire.com/news-release/2024/04/24/2869078/0/en/Erasca-Announces-Three-Presentations-at-the-2024-ASCO-Annual-Meeting.html
https://www.globenewswire.com/news-release/2024/03/28/2853682/0/en/Erasca-Announces-45-Million-Oversubscribed-Private-Placement-Financing.html
https://www.globenewswire.com/news-release/2024/03/27/2853585/0/en/Erasca-Reports-Fourth-Quarter-2023-and-Full-Year-2023-Business-Updates-and-Financial-Results.html
https://www.globenewswire.com//news-release/2024/02/14/2829047/0/en/Erasca-Announces-Two-Clinical-Trial-Collaboration-and-Supply-Agreements-for-Trametinib-to-Evaluate-Naporafenib-Combination-in-SEACRAFT-1-and-SEACRAFT-2-Trials.html